Sun Pharma Q2 Profit Falls 36% on Exceptional Charges; Revenue Rises Nearly 12%
Sun Pharmaceutical Industries reported a 36 percent year-on-year decline in consolidated net profit to around Rs 1,989 crore for Q2 FY27, mainly due to exceptional charges totaling approximately Rs 1,269 crore. These included a US antitrust litigation settlement and costs related to its proposed acquisition of Organon. Despite this, revenue grew nearly 12 percent to about Rs 16,199 crore, driven by strong domestic formulation sales and growth in emerging markets. Adjusted net profit excluding exceptional items rose slightly, with EBITDA margins at 29.3 percent.
First-hand measurement across 7 sources
We measured how 7 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (50/100). Lens Score 38/100.
Outlets measured: economictimes, thehindu, businessstandard, news18, economictimes, economictimes, moneycontrol. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (42–52/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
moneycontrol broke this story on 30 Oct, 09:02 am. Other outlets followed.